Investigations into CH within oncological cohorts have yielded a consistent observation: cancer patients exhibit a mutational bias toward genes that are part of the DNA-damage response (DDR) pathway, including but not limited to TP53, PPM1D, and CHEK2 (4, 5). This evidence concerns the gene CHEK2 and cyclic hematopoiesis.